Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) is 35.41% higher on its value in year-to-date trading and has touched a low of $31.52 and a high of $68.58 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RYTM stock was last observed hovering at around $61.95 in the last trading session, with the day’s gains setting it 0.3%.
Currently trading at $62.25, the stock is 4.93% and 15.49% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.43 million and changing 0.48% at the moment leaves the stock 35.40% off its SMA200. RYTM registered 93.86% gain for a year compared to 6-month gain of 69.71%. The firm has a 50-day simple moving average (SMA 50) of $53.728 and a 200-day simple moving average (SMA200) of $45.9075.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 25.66% loss in the last 1 month and extending the period to 3 months gives it a 35.03%, and is 4.87% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.99% over the week and 5.48% over the month.
Rhythm Pharmaceuticals Inc (RYTM) has around 226 employees, a market worth around $3.83B and $112.53M in sales. Profit margin for the company is -232.41%. Distance from 52-week low is 97.46% and -9.23% from its 52-week high. The company has generated returns on investments over the last 12 months (-98.33%).
The EPS is expected to shrink by -36.17% this year
254.0 institutions hold shares in Rhythm Pharmaceuticals Inc (RYTM), with institutional investors hold 115.91% of the company’s shares. The shares outstanding are 59.43M, and float is at 54.81M with Short Float at 12.24%. Institutions hold 115.30% of the Float.
The top institutional shareholder in the company is PRIMECAP MANAGEMENT CO/CA/ with over 7.31 million shares valued at $300.25 million. The investor’s holdings represent 12.1582 of the RYTM Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 6.74 million shares valued at $276.82 million to account for 11.2097 of the shares outstanding. The other top investors are BAKER BROS. ADVISORS LP which holds 6.4 million shares representing 10.6385 and valued at over $262.72 million, while RA CAPITAL MANAGEMENT, L.P. holds 10.1165 of the shares totaling 6.08 million with a market value of $249.83 million.
Rhythm Pharmaceuticals Inc (RYTM) Insider Activity
The most recent transaction is an insider sale by Lee Jennifer Kayden, the company’s EVP, Head of North America. SEC filings show that Lee Jennifer Kayden sold 66,861 shares of the company’s common stock on Nov 11 ’24 at a price of $66.33 per share for a total of $4.43 million. Following the sale, the insider now owns 972.0 shares.
Rhythm Pharmaceuticals Inc disclosed in a document filed with the SEC on Nov 11 ’24 that Shulman Joseph (Chief Technical Officer) sold a total of 13,281 shares of the company’s common stock. The trade occurred on Nov 11 ’24 and was made at $66.44 per share for $0.88 million. Following the transaction, the insider now directly holds 0.0 shares of the RYTM stock.
Still, SEC filings show that on Nov 11 ’24, JENNIFER KAYDEN LEE (Officer) Proposed Sale 66,861 shares at an average price of $67.33 for $4.5 million. The insider now directly holds shares of Rhythm Pharmaceuticals Inc (RYTM).
